Abstract: Multiple myeloma is a hematologic malignancy originating from bone marrow plasma cells and remains incurable. Most patients eventually develop into relapsed／refractory multiple myeloma. Bispecific antibody therapy is a promising immunotherapeutic approach that has initially demonstrated significant efficacy. This article will review research progress of bispecific antibody in treatment of relapsed／refractory multiple myeloma.

Key words: bispecific antibody, relapsed／refractory multiple myeloma, targeted therapy, clinical trial